ValiRx PLC Formation of & Appointments to an Advisory Board
June 22 2017 - 2:00AM
RNS Non-Regulatory
TIDMVAL
ValiRx PLC
22 June 2017
ValiRx Plc
("ValiRx" or the "Company")
FORMATION OF & APPOINTMENTS TO AN ADVISORY BOARD
London, UK., 22 June 2017: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company, is pleased to announce the formation
of an Advisory Board ("AB") and that the following individuals have
agreed to join it and to offer ValiRx the benefit of their
experience, spanning venture capital, life science and finance.
ValiRx's newly formed Advisory Board has been created to provide
strategic guidance and technical advice to the Company's main
board. AB members will be responsible for monitoring sector
developments and licensing opportunities in the life-science space,
as well as supporting ValiRx in accessing partnering opportunities
via members' extensive network of contacts.
Seppo Mäkinen
Seppo Mäkinen, previously a ValiRx Non-Executive Director, has
more than 30 years of senior advisory and executive experience in
board level strategic leadership and venture capital management on
life science. His career includes ten years as director in Life
Sciences at Sitra (Finnish Government Fund), followed by 13 years
as co-founder and Managing Partner in Bio Fund Management Oy. In
2010, Seppo founded Taikon Advisor Oy, a Finnish management
consultancy firm focusing on advising and investing in life
sciences ventures. He stepped down from the ValiRx Board in May
2017.
Dr Ajay Agrawal
Dr Ajay K Agrawal is currently the Chief Business Officer at
ValiRx. He is an experienced entrepreneur in the biotech and pharma
industry, who currently sits on the boards of companies in the UK,
Europe and USA, assisting them in shaping their aims, values, and
strategic goals. He also sits on the editorial board of six
peer-reviewed international scientific journals from Bentham Press,
California, USA, and he is the Managing Director Europe and
Advisory Board Member of Ignite Capital Partners, USA and a trustee
of the Ramphal Institute, London. Previously, Ajay was a founder of
polyMASC Pharmaceuticals plc, London, the first UK biotech company
from a university (Royal Free Hospital School of Medicine,
University of London) that was directly listed on the London Stock
Exchange, raising approximately $40 million in 1995, before its
subsequent merger with the NASDAQ-listed company, Valentis Inc in
1999. He was a Board Director and member of the remuneration &
audit committees of Immupharma plc, the AIM-listed pharmaceutical
development company for over eight years.
Andrew King
Andrew King has almost twenty years' experience working in the
biotech and life-science sectors. He served for nearly ten years as
Finance Director of the extremely successful AIM listed biotech
company, NeuTec Pharma Limited, leading the business through its
IPO to its subsequent sale in 2006 to Novartis Pharma AG for GBP305
million. He has experience across a range of sectors and has served
as Finance Director and company secretary to a number of
organisations including Hutchison Whampoa (Europe) Limited, Utility
Cable plc and Umbro.com Limited. Most recently he served for five
years as CFO to Smart Matrix Limited, a start-up medtech business
spun out of a medical research charity. Since 2016 he has acted as
an Associate Partner with St. James's Place Wealth Management plc.
He is a qualified Chartered Accountant (Price Waterhouse) and has a
degree in law.
Dr Satu Vainikka, Chief Executive Officer of ValiRx,
commented:
I would like to extend a warm welcome to our Advisory Board and
am delighted that we have attracted such experienced and talented
individuals to our team. I strongly believe that their counsel and
ability to draw on such a spread of proven experience and contacts
in our sector, will be of substantial benefit to ValiRx and in the
shaping of its strategic direction.
For more information, please contact:
ValiRx plc Tel: +44 (0) 20
3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20
3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Beaufort Securities Limited Tel: +44 (0) 207
(Broker) 382 8300
Jon Belliss
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from world-class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUQGQUPMGQG
(END) Dow Jones Newswires
June 22, 2017 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024